Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 20/20 | 0.79 |
| ▸ | BCR | P11274 | 13/20 | 0.79 |
| ▸ | LYN | P07948 | 9/20 | 0.79 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.79 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.79 |
| ▸ | LCK | P06239 | 1/20 | 0.79 |
| ▸ | FYN | P06241 | 1/20 | 0.79 |
| ▸ | RET | P07949 | 1/20 | 0.79 |
| ▸ | ARAF | P10398 | 1/20 | 0.79 |
| ▸ | BRAF | P15056 | 1/20 | 0.79 |
| ▸ | NQO2 | P16083 | 1/20 | 0.79 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.79 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.79 |
| ▸ | CSK | P41240 | 1/20 | 0.79 |
| ▸ | ABL2 | P42684 | 1/20 | 0.79 |
| ▸ | FRK | P42685 | 1/20 | 0.79 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.79 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.79 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.79 |
| ▸ | EPHA5 | P54756 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3559257 | 1.00 | ABL1 (0.79) | ABL1BCRLYNPDGFRBRIPK2 | |
| SCHEMBL3563789 | 1.00 | ABL1 (0.79) | ABL1BCRLYNPDGFRBRIPK2 | |
| Hydrochloric Acid SCHEMBL3562840 | 0.99 | ABL1 (0.80) | ABL1BCRLYNPDGFRBRIPK2 | |
| Hydrochloric Acid SCHEMBL3562844 | 0.99 | ABL1 (0.80) | ABL1BCRLYNPDGFRBRIPK2 | |
| SCHEMBL3563286 | 0.93 | ABL1 (0.76) | ABL1BCRLYNPDGFRBRIPK2 | |
| Hydrochloric Acid SCHEMBL3565629 | 0.92 | ABL1 (0.76) | ABL1BCRLYNPDGFRBRIPK2 | |
| SCHEMBL3560129 | 0.91 | ABL1 (0.86) | ABL1BCRLYNPDGFRBRIPK2 | |
| SCHEMBL3558396 | 0.90 | ABL1 (0.84) | ABL1BCRLYNPDGFRBRIPK2 | |
| SCHEMBL3558392 | 0.90 | ABL1 (0.84) | ABL1BCRLYNPDGFRBRIPK2 | |
| SCHEMBL3562812 | 0.90 | ABL1 (0.84) | ABL1BCRLYNPDGFRBRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1702917-B1 | AMIDE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO LTD (JP) | 2017-08-02 | — | — | EP | claimed |
| CN-101456841-A | Amide derivative and medicine | NIPPON SHINYAKU CO LTD (JP) | 2009-06-17 | — | — | CN | claimed |
| US-20080293940-A1 | Amide Derivative and Medicine | NIPPON SHINYAKU CO., LTD. (JP) | 2008-11-27 | — | — | US | claimed |
| CN-1898208-A | Amide derivative and pharmaceutical | NIPPON SHINYAKU CO LTD (JP) | 2007-01-17 | — | — | CN | claimed |
| EP-1702917-A1 | AMIDE DERIVATIVE AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2006-09-20 | — | — | EP | claimed |
| EP-3299358-A1 | AMIDE DERIVATIVE AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2018-03-28 | — | — | EP | disclosed |
| EP-1702917-B1 | AMIDE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO LTD (JP) | 2017-08-02 | — | — | EP | disclosed |
| US-7728131-B2 | 3-difluoromethyl-4-(4-methylpiperazin-1-ylmethyl)-N-{4-methyl-3-[4-(5-pyrimidinyl)pyrimidin-2-ylamino]phenyl}benzamide, having excellent tyrosine kinase inhibitory activity, used as therapeutic agent for leukemia | NIPPON SHINYAKU CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| CN-100526298-C | Amide derivative and pharmaceutical | NIPPON SHINYAKU CO LTD (JP) | 2009-08-12 | — | — | CN | disclosed |
| CN-101456841-A | Amide derivative and medicine | NIPPON SHINYAKU CO LTD (JP) | 2009-06-17 | — | — | CN | disclosed |
| US-20080293940-A1 | Amide Derivative and Medicine | NIPPON SHINYAKU CO., LTD. (JP) | 2008-11-27 | — | — | US | disclosed |
| CN-1898208-A | Amide derivative and pharmaceutical | NIPPON SHINYAKU CO LTD (JP) | 2007-01-17 | — | — | CN | disclosed |
| EP-1702917-A1 | AMIDE DERIVATIVE AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2006-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293940-A1 | Amide Derivative and Medicine | ABL2, ABL1, BCR | ABL1 2/4885BCR 3/4885LYN 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.